Fewer people could be recommended for primary prevention statin therapy, including many younger adults with high long-term cardiovascular disease risk, if physicians adhere to the 2016 US Preventive Services Task Force (USPSTF) recommendations for statin therapy compared with the 2013 American College of Cardiology/American Heart Association guidelines, according to a study.
Traffic-related air pollution may increase risk of developing cardiovascular diseases through its effects on high-density lipoprotein (HDL), also known as 'good' cholesterol. US middle-aged and older adults living in areas with high levels of traffic-related air pollution tended to have lower levels of good cholesterol. Changes in HDL levels were observed after brief and medium-length exposures to air pollution.
Cardiac glycosides reduce a precursor of LDL cholesterol in a drug screen of statin-resistant hypercholesterolemia, new research concludes. A large meta-analysis of medical records revealed that patients taking glycosides for heart failure had reductions in LDL cholesterol similar to patients taking statins. Cardiac glycosides are a potential treatment for patients with high cholesterol who don't respond to statins.
Exposure during infancy to the common plasticizer bisphenol A (BPA) "hijacks" and reprograms genes in the liver of newborn rats, leading to nonalcoholic fatty liver disease (NAFLD) in adulthood. A new study has found how this process occurs.
Body weight plays a significant role in how much benefit children may get from consuming “good” fats, new research suggests. The study highlights the need for weight-appropriate dosing of supplements and medications.
As little as 10 minutes a day of high-intensity physical activity could help some children reduce their risk of developing heart problems and metabolic diseases such as diabetes, according to an international study.
Even a single dose of a specific ribonucleic acid molecule, known as a small interfering RNA (siRNA), offers patients at high risk of cardiovascular disease long-lasting protection against high LDL cholesterol -- one of the main risk factors for heart attack and stroke -- conclude researchers.
Researchers are revisiting their views on the relative dangers soft and hard atherosclerotic plaque deposits pose to heart health. Findings of a new study may be a "game-changer" for determining who's at risk of a heart attack, they say.
Researchers have developed a new way of visualizing the distribution of cholesterol in cells and tissues. Their research provides insights into the movement of cholesterol into and out of cells and could eventually identify mechanisms linking cholesterol to coronary artery disease.
Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease. But in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease.
An 80-year-old from the Tsimane (pronounced chee-MAH-nay) group had the same vascular age as an American in his or her mid-fifties, suggests a new report. The Tsimane people -- a forager-horticulturalist population of the Bolivian Amazon -- have the lowest reported levels of vascular aging for any population, with coronary atherosclerosis (hardening of the arteries) being five times less common than in the US, the research shows.
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of cardiovascular events in patients with existing heart or vascular disease already on statin therapy, according to new research.
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the arteries of patients who had recently had a heart attack did not reduce the volume of fatty deposits, or plaque, in the arteries, compared with placebo injections, according to new research.
New research suggests that GlycA, a newly identified blood marker, and C-reactive protein both independently predict major adverse cardiac events, including heart failure and death. Patients who have high levels of both biomarkers are at especially high risk.
Among adults who entered a study more than 25 years ago, an increasing number of midlife vascular risk factors, such as obesity, high blood pressure, diabetes, high cholesterol and smoking, were associated with elevated levels of brain amyloid (protein fragments linked to Alzheimer's disease) later in life, report researchers.